US 7601713
Kinase inhibitors and their uses
granted A61KA61K31/517A61P
Quick answer
US patent 7601713 (Kinase inhibitors and their uses) held by Rigel Pharmaceuticals, Inc. expires Mon Oct 08 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Oct 13 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 08 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 42
- CPC classes
- A61K, A61K31/517, A61P, A61P1/04, A61P1/18